piracetam has been researched along with Adverse Drug Event in 22 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the feasibility and safety of intravenous (iv) levetiracetam (LEV) added to the standard therapeutic regimen in adults with status epilepticus (SE), and as secondary objective to assess a population pharmacokinetic (PK) model for ivLEV in patients with SE." | 9.14 | Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ( Engelsman, J; Peeters, E; Touw, DJ; Uges, JW; van Huizen, MD; Vecht, CJ; Wilms, EB, 2009) |
| "The objective of this study was to determine whether levetiracetam (LEV) is an effective drug for treatment of trigeminal neuralgia (TN)." | 9.14 | Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. ( Johnston, A; Jorns, TP; Zakrzewska, JM, 2009) |
| "Levetiracetam (LEV) is an anti-seizure medication (ASM) known to have significant behavioral side effects in children with epilepsy." | 8.12 | Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study. ( Bartolini, L; Bassell-Hawkins, J; Lob, K; Nie, D; Patil, R, 2022) |
| "In 2006, intravenous levetiracetam received US Food and Drug Administration (FDA) approval for adjunctive treatment of partial onset seizures in adults with epilepsy, 16 years or older." | 7.76 | Intravenous levetiracetam in children with seizures: a prospective safety study. ( Cardenas, JF; Chapman, KE; Hastriter, EV; Khoury, EM; Ng, YT, 2010) |
| " The onset of signs/symptoms usually occurs early, even during the titration phase, and, in many cases, at a low dosage (<20 mg/kg/day)." | 6.46 | Levetiracetam in childhood epilepsy. ( Chiarelli, F; Curatolo, P; D'Adamo, E; Parisi, P; Verrotti, A, 2010) |
| "This study was a randomized double-blind placebo-controlled clinical trial on 53 adult patients with epilepsy with behavioral side effects after treatment by levetiracetam." | 5.51 | Pyridoxine for treatment of levetiracetam-induced behavioral adverse events: A randomized double-blind placebo-controlled trial. ( Alizadeh-Navaei, R; Asghari, F; Cheraghmakani, H; Ghazaeian, M; Rezapour, M; Tabrizi, N, 2022) |
| "To evaluate the feasibility and safety of intravenous (iv) levetiracetam (LEV) added to the standard therapeutic regimen in adults with status epilepticus (SE), and as secondary objective to assess a population pharmacokinetic (PK) model for ivLEV in patients with SE." | 5.14 | Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ( Engelsman, J; Peeters, E; Touw, DJ; Uges, JW; van Huizen, MD; Vecht, CJ; Wilms, EB, 2009) |
| "The objective of this study was to determine whether levetiracetam (LEV) is an effective drug for treatment of trigeminal neuralgia (TN)." | 5.14 | Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. ( Johnston, A; Jorns, TP; Zakrzewska, JM, 2009) |
| "The aim of this study was to assess the relationship between levetiracetam dose and both efficacy and safety in adult patients with refractory partial epilepsy." | 5.12 | Assessment of a dose-response relationship of levetiracetam. ( Buyle, S; Meencke, HJ, 2006) |
| "Levetiracetam (LEV) is an anti-seizure medication (ASM) known to have significant behavioral side effects in children with epilepsy." | 4.12 | Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study. ( Bartolini, L; Bassell-Hawkins, J; Lob, K; Nie, D; Patil, R, 2022) |
| "To prospectively evaluate the safety of levetiracetam oral solution and its impact on epilepsy severity in infants with different seizure types." | 3.83 | Safety of levetiracetam among infants younger than 12 months--Results from a European multicenter observational study. ( Arzimanoglou, A; Bentz, J; Garate, P; Lösch, C, 2016) |
| "In 2006, intravenous levetiracetam received US Food and Drug Administration (FDA) approval for adjunctive treatment of partial onset seizures in adults with epilepsy, 16 years or older." | 3.76 | Intravenous levetiracetam in children with seizures: a prospective safety study. ( Cardenas, JF; Chapman, KE; Hastriter, EV; Khoury, EM; Ng, YT, 2010) |
| "Both levetiracetam (LEV) and phenytoin (PHT) were associated with a low risk of early postoperative seizures and a moderate risk of later epilepsy." | 3.74 | Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. ( Bromfield, EB; Hurwitz, S; Milligan, TA, 2008) |
| " No dose-response relationship was demonstrated; however, the odds of a levetiracetam-naive patient, (median dose, 26." | 2.50 | An 11-year review of levetiracetam ingestions in children less than 6 years of age. ( Albertson, TE; Lewis, JC; Walsh, MJ, 2014) |
| " The onset of signs/symptoms usually occurs early, even during the titration phase, and, in many cases, at a low dosage (<20 mg/kg/day)." | 2.46 | Levetiracetam in childhood epilepsy. ( Chiarelli, F; Curatolo, P; D'Adamo, E; Parisi, P; Verrotti, A, 2010) |
| "There were 12 patients with documented adverse drug events during the study period, with four potentially directly related to IV push LEV administration." | 1.62 | Rapid administration of undiluted intravenous levetiracetam. ( Bonnin, S; Haller, JT; Radosevich, J, 2021) |
| "At baseline, patients with focal-onset seizures (189 of 942; 20." | 1.46 | Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. ( Brodie, MJ; Stephen, LJ; Wishart, A, 2017) |
| "All patients ≥16years of age with epilepsy for ≥12months were routinely asked to complete the Liverpool Adverse Event Profile (LAEP) just before their appointment." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "When lamotrigine was restarted 2 weeks later she developed similar but more severe symptoms which resolved on stopping lamotrigine." | 1.35 | Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis. ( Bazaz, R; Lily, O; Maniyar, F; Rooney, C, 2009) |
| " Bioavailability of IM LEV was 100%." | 1.35 | Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. ( Cloyd, JC; Dunn, AW; Fisher, JE; Goel, V; Leppik, IE; O'Brien, TD; Patterson, EE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| García, FG | 1 |
| Cardon, M | 1 |
| Cardon, AL | 1 |
| Reinert, JP | 1 |
| Maktabi, L | 1 |
| Branam, D | 1 |
| Snyder, M | 1 |
| Lob, K | 1 |
| Bassell-Hawkins, J | 1 |
| Patil, R | 1 |
| Nie, D | 1 |
| Bartolini, L | 1 |
| Cheraghmakani, H | 1 |
| Rezapour, M | 1 |
| Asghari, F | 1 |
| Alizadeh-Navaei, R | 1 |
| Ghazaeian, M | 1 |
| Tabrizi, N | 1 |
| Haller, JT | 1 |
| Bonnin, S | 1 |
| Radosevich, J | 1 |
| Stephen, LJ | 1 |
| Wishart, A | 1 |
| Brodie, MJ | 1 |
| Gillinder, L | 1 |
| Lehn, A | 1 |
| Brown, H | 1 |
| Dionisio, S | 1 |
| Özkale, Y | 1 |
| Özkale, M | 1 |
| Saygi, S | 1 |
| Erol, I | 1 |
| Lewis, JC | 1 |
| Albertson, TE | 1 |
| Walsh, MJ | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Arzimanoglou, A | 1 |
| Lösch, C | 1 |
| Garate, P | 1 |
| Bentz, J | 1 |
| Redkar, N | 1 |
| Rawat, KJ | 1 |
| Shah, JH | 1 |
| Jena, AB | 1 |
| Agrawal, V | 1 |
| Milligan, TA | 1 |
| Hurwitz, S | 1 |
| Bromfield, EB | 1 |
| Uges, JW | 1 |
| van Huizen, MD | 1 |
| Engelsman, J | 1 |
| Wilms, EB | 1 |
| Touw, DJ | 1 |
| Peeters, E | 1 |
| Vecht, CJ | 1 |
| Maniyar, F | 1 |
| Rooney, C | 1 |
| Lily, O | 1 |
| Bazaz, R | 1 |
| Jorns, TP | 1 |
| Johnston, A | 1 |
| Zakrzewska, JM | 1 |
| Ng, YT | 1 |
| Hastriter, EV | 1 |
| Cardenas, JF | 1 |
| Khoury, EM | 1 |
| Chapman, KE | 1 |
| Verrotti, A | 1 |
| D'Adamo, E | 1 |
| Parisi, P | 1 |
| Chiarelli, F | 1 |
| Curatolo, P | 1 |
| Robins, A | 1 |
| Patel, M | 1 |
| Azim, A | 1 |
| Meencke, HJ | 1 |
| Buyle, S | 1 |
| Patterson, EE | 1 |
| Goel, V | 1 |
| Cloyd, JC | 1 |
| O'Brien, TD | 1 |
| Fisher, JE | 1 |
| Dunn, AW | 1 |
| Leppik, IE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for piracetam and Adverse Drug Event
| Article | Year |
|---|---|
Clinical considerations for rapid administration of undiluted or minimally diluted levetiracetam bolus doses.
Topics: Administration, Intravenous; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Human | 2022 |
An 11-year review of levetiracetam ingestions in children less than 6 years of age.
Topics: Anticonvulsants; California; Child, Preschool; Dose-Response Relationship, Drug; Drug-Related Side E | 2014 |
Levetiracetam in childhood epilepsy.
Topics: Animals; Child; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Human | 2010 |
4 trials available for piracetam and Adverse Drug Event
| Article | Year |
|---|---|
Pyridoxine for treatment of levetiracetam-induced behavioral adverse events: A randomized double-blind placebo-controlled trial.
Topics: Adult; Anticonvulsants; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Epilep | 2022 |
Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Bayes Theorem; Biological Availability; Dose-Response Relationship, Dr | 2009 |
Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Sche | 2009 |
Assessment of a dose-response relationship of levetiracetam.
Topics: Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eva | 2006 |
15 other studies available for piracetam and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Observations Regarding Recently Published Amelioration of Levetiracetam-Induced Behavioral Side Effects by Pyridoxine.
Topics: Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Humans; Levetiracetam; Piracetam; | 2022 |
Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study.
Topics: Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Levetirac | 2022 |
Rapid administration of undiluted intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Levetirac | 2021 |
Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dibenzazepines; Drug-Relate | 2017 |
Treatment outcomes after the introduction of a new seizure management protocol.
Topics: Adult; Anticonvulsants; Clinical Protocols; Drug-Related Side Effects and Adverse Reactions; Emergen | 2018 |
Long-term accidental overdose of levetiracetam in an infant.
Topics: Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Female; Follow-Up Studie | 2014 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Safety of levetiracetam among infants younger than 12 months--Results from a European multicenter observational study.
Topics: Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Europe; Female; Humans; | 2016 |
An Unusual Side Effect Of A Commonly Used Antiepileptic Drug.
Topics: Agranulocytosis; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Fever; | 2016 |
Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain; Brain Injuries; Drug Tolerance; Drug-Related | 2008 |
Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis.
Topics: Anti-Bacterial Agents; Anticonvulsants; Drug Administration Schedule; Drug-Related Side Effects and | 2009 |
Intravenous levetiracetam in children with seizures: a prospective safety study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side E | 2010 |
A case of physical and mental adverse drug reactions associated with levetiracetam in post-stroke epilepsy.
Topics: Aged; Anticonvulsants; Cognition; Disease Progression; Drug-Related Side Effects and Adverse Reactio | 2012 |
Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.
Topics: Absorption; Administration, Oral; Animals; Anticonvulsants; Area Under Curve; Biological Availabilit | 2008 |